Hot Information Technology Stocks To Buy Right Now

This year has been pretty good so far for Cerner (NASDAQ: CERN  ) shareholders. As of market close on Thursday, the stock was up nearly 15% year to date. That performance just might improve now that the large health information technology company has announced its first-quarter results. Shares were up more than 1% in after-hours trading. Here are the highlights.

By the numbers
Cerner reported adjusted net earnings during the quarter of $116.9 million, or $0.66 per share. That's 24% higher than the same quarter of 2012. It also beat the consensus analysts' estimate of $0.63 per share.

GAAP earnings came in at $110 million, or $0.62 per share. That result compares with $88.7 million in earnings and diluted earnings per share of $0.51 in the first quarter of last year.

Revenue for the quarter totaled $680 million, up 6% year over year. However, that amount missed the average analysts' estimate of $708.5 million and was less than what Cerner expected.

Top 5 Asian Stocks To Own For 2015: United-Guardian Inc.(UG)

United-Guardian, Inc. researches, develops, manufactures, and markets cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products in the United States, Canada, China, France, and internationally. Its personal care products include LUBRAJEL, a line of water-based moisturizing and lubricating gel formulations; KLENSOFT, a surfactant for cosmetic formulations; UNITWIX, a cosmetic additive used as a thickener for oils and oil-based liquids; CONFETTI DERMAL DELIVERY FLAKES for use in various water-based products; ORCHID COMPLEX, a base for cosmetics; LUBRASLIDE and B-122 lubricants used in cosmetics; AQUATHIK, a powder used as a gelling agent for aqueous solutions or emulsions; and HYDRAJEL PL, a personal lubricant for the feminine personal care market. The company?s medical products comprise LUBRAJEL RR and RC water-based gels used as lubricants for catheters; LUBRAJEL MG to lubricate urinary catheters, prelubricated enema tips, and other medical devices; LUBRAJEL LC, a mouth moisturizer for oral use; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceuticals consists of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial for use in urology and surgery to treat infections in the urinary bladder. United-Guardian?s industrial products include DESELEX Liquid, a sequestering and chelating agent; and POLYCOMPLEX M and Q complexing agents to produce clear solutions of water-insoluble materials. The company distributes its products to drug wholesalers, drug stores, hospitals, physicians, long-term care facilities, Veteran?s Administration, and other government agencies through marketing partners, distributors, advertising in medical and trade journals, mailings to physicians, and exhibitions. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.

Advisors' Opinion:

• [By Dorothee Tschampa]

  Volkswagen AG (VOW) (VOW), PSA Peugeot Citroen (UG) and Renault SA (RNO) (RNO), Europe�� three largest carmakers, all dropped 5 percent or more after preliminary data showed Chinese manufacturing is unexpectedly contracting.

• [By Inyoung Hwang]

  PSA Peugeot (UG) Citroen climbed to a 17-month high after saying it won�� cut prices for the Peugeot brand. Glencore Xstrata Plc advanced 2.3 percent after raising its estimate for financial gains from its merger with Xstrata Plc. Neste Oil Oyj surged to a five-year high after upgrading its full-year forecast. GlaxoSmithKline Plc slid 2.5 percent as new U.S. guidelines opened the door for generic versions of its Advair drug.

• [By Marc Bastow]

  Cosmetics maker United-Guardian (UG) raised its semi-annual dividend 13% to 50 cents per share, payable on Dec. 20 to shareholders of record as of Dec. 6. This marks the 37th consecutive annual increase to the dividend.
  UG Dividend Yield: 4.86%

Hot Information Technology Stocks To Buy Right Now: Investment Technology Group Inc (ITG)

Investment Technology Group, Inc. (ITG), incorporated on March 10, 1994, is an independent execution and research broker that partners with global portfolio managers and traders to provide data-driven insights throughout the investment process. It operates in three segments: United States Operations, Canadian Operations, European Operations and Asia Pacific Operations. The United States Operations segment provides electronic and trade execution, trade order and execution management, network connectivity, analytical products and investment research services. The Canadian and Asia Pacific Operations segments provide electronic and high-touch trade execution, trade execution management, network connectivity, analytical products and investment research services. The European Operations segment provides electronic and high-touch trade execution, trade order and execution management, network connectivity and analytical products and includes a technology research and development facility in Israel.

ITG offers a range of solutions for asset managers in the areas of electronic brokerage, research sales and trading, trading platforms and analytics. These offerings include trade execution services and solutions for portfolio management, as well as investment research, pre-trade analytics and post-trade analytics and processing. Its principal subsidiaries include: ITG Inc., AlterNet Securities, Inc., ITG Derivatives LLC, Investment Technology Group Limited, ITG Australia Limited, ITG Canada Corp., ITG Hong Kong Limited, ITG Software Solutions, Inc. and ITG Solutions Network, Inc.

Electronic Brokerage

ITG electronic brokerage services include self-directed trading using algorithms, smart routing and matching through POSIT in cash equities (including single stocks and portfolio lists), futures and options. ITG Algorithms and ITG Smart Router offer portfolio managers and traders a way to trade orders quickly, from any ITG Execution Management System (EMS) or ITG Order Managemen! t System (OMS) and third-party trading platforms. ITG Algorithms help users pursue execution through two suites: ITG Single Stock Algorithms and ITG List-Based Algorithms. ITG Smart Router offers an alternative to routing trades that can help capture liquidity with a combination of speed and confidentiality. These routers continuously scan markets for liquidity with an emphasis on trading without displaying the order.

POSIT Alert is a buyside-only block crossing mechanism within POSIT. POSIT Alert scans uncommitted shares from participating clients. When a crossing opportunity is detected, POSIT Alert notifies the relevant users that a matching opportunity exists. POSIT Marketplace provides access to POSIT liquidity, the dark pools of other ATSs, and certain exchange hidden order types. POSIT Marketplace is a dark pool aggregator that provides clients with access to a range of liquidity destinations. POSIT Marketplace uses advanced quantitative techniques in an effort to protect clients from gaming and to interact with quality liquidity. ITG Derivatives provides electronic-listed futures and options trading, including algorithmic trading and direct market access. ITG offers options features for traders employing volatility or delta-neutral strategies and also provides low-latency application programming interfaces.

ITG offers guidance, administration, and consolidation of client commission arrangements across the range of preferred brokerage and research providers of its clients using ITG Commission Manager, a robust, multi-asset Web-based commission management portal. Through stock borrow and stock loan transactions, ITG facilitates shortened or extended settlement periods to help clients meet their internal cash flow needs.

Research Sales & Trading

ITG provides unbiased, data-driven equity research through its ITG Investment Research subsidiary. This offering has expanded ITG's client relationships beyond the trading desk to chief investment officer! s, portfo! lio managers and analysts. ITG Market Research offers market research capabilities to corporate clients within the healthcare and telecom industries. The healthcare market research practice combines survey results with empirical data to deliver syndicated and custom reporting capabilities. ITG provides high-touch sales trading and portfolio trading for institutional clients. ITG's high-touch trading desk is staffed with experienced trading professionals who provide ITG clients with execution expertise and also convey trading ideas based on ITG Investment Research.

Trading Platforms

ITG EMSs are designed to meet the needs of disparate trading styles. Triton Derivatives is a broker-neutral direct access EMS that provides traders with access to scalable, low-latency, multi-asset trading opportunities. ITG OMS combines portfolio management, compliance functionality (ITG Compliance Monitoring System), trading and post-trade processing (ITG Trade Operations Outsourcing), and a fully integrated and supported financial services communications network (ITG Net) with a consolidated, outsourced service for global trade matching and settlement (ITG Trade Operations Outsourcing) that provides connectivity to the industry's post-trade utilities, support for multiple, flexible settlement communications methods and a real-time process monitor. ITG Net is a global financial communications network that provides secure, reliable and fully supported connectivity between buy-side and sell-side firms for order routing and indication-of-interest messages from ITG and third-party trading platforms.

ITG's commitment to execution platforms also extends to broker-neutral operational services to help ensure that trades clear and settle efficiently, and to significantly lower the transaction costs associated with trade tickets. The ITG Smart Trading Analytics suite enables portfolio managers and traders to improve execution performance before the trade happens (pre-trade) and during trading ! (real-tim! e) by providing reliable portfolio analytics and risk models that help them perform predictive analyses, manage risk, change strategy and reduce trading costs. ITG Transaction Cost Analysis (TCA) offers measurement and reporting capabilities to analyze performance across the trading continuum. ITG Alpha Capture Reporting measures cost at every point of the investment process and provides portfolio managers with quarterly analytical reviews, written interpretations and on-site consultative recommendations to enhance performance.

ITG provides tools to assist asset managers with portfolio decision-making tasks from portfolio construction and optimization to the enterprise challenges of global, real-time portfolio compliance monitoring and the fair valuation of securities. ITG Portfolio Fair Value Service helps mutual fund managers meet their obligations to investors and regulators to fairly price the securities within their funds, and helps minimize the impact of market timing. ITG Portfolio Optimization System allows portfolio managers to develop new portfolio construction strategies and solve complex optimization problems. ITG Portfolio Optimization System allows users to accurately model tax liability, transaction costs and long/short objectives, while adhering to diverse portfolio-specific constraints.

Non-U.S. Operations

ITG has a development center in Tel Aviv. In Asia Pacific, ITG has offices in Sydney, Melbourne, Hong Kong and Singapore. Local representation in regional markets provides an important advantage for ITG. ITG also provides electronic and high-touch trading for Latin American equities, including algorithms for Brazil and Mexico, from its New York headquarters.

Canadian Operations

ITG Canada provides electronic brokerage services, including ITG Algorithms, ITG Smart Router and the POSIT suite, as well as high-touch agency execution and portfolio trading services. In addition, ITG Canada provides Triton, Triton Derivatives! , connect! ivity services, ITG Single Ticket Clearing, ITG Portfolio Optimization System, ITG Smart Trading Analytics, ITG TCA and investment research services. ITG Canada also engages in principal trading activities. ITG Canada's customers primarily consist of asset and investment managers, broker-dealers and hedge funds.

European Operations

ITG Europe focuses on trading European, Middle Eastern and African equities, as well as providing ITG's technologies to its clients. ITG Europe provides electronic brokerage services, including ITG Algorithms, ITG Smart Router, and the POSIT suite, as well as high-touch agency execution and portfolio trading services. ITG Europe also provides ITG OMS, Triton, connectivity services, ITG Single Ticket Clearing, ITG TCA, ITG Alpha Capture Reporting and ITG Smart Trading Analytics.

Asia Pacific Operations

ITG provides institutional investors with a range of ITG's products and services including trade execution, trade execution management through Triton, connectivity services and pre-and post-trade analysis through ITG TCA and ITG Smart Trading Analytics. Execution services are provided through electronic brokerage products such as ITG Algorithms and the POSIT suite and through an experienced high-touch agency trading services team. Other trading tools provided by ITG Hong Kong include Triton, connectivity services, ITG TCA and ITG Smart Trading Analytics. ITG Singapore provides institutional investors in Singapore with a range of ITG's products and services including electronic and high-touch execution services, trade execution management through Triton and trading analysis through ITG TCA and ITG Smart Trading Analytics.

Advisors' Opinion:

• [By Jon C. Ogg]

  Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by Keefe�Bruyette & Woods.

  Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

Hot Information Technology Stocks To Buy Right Now: Glencore Xstrata PLC (GLENN)

Glencore Xstrata Plc is a diversified natural resource company. The Company operates in three segments: Metals and Minerals, which includes copper, nickel, zinc/lead, alloys, alumina/aluminum and iron ore; Energy Products, which includes controlled and non-controlled coal mining and oil production operations and investments in strategic handling, storage and freight equipment and facilities, and Agricultural Products, which focuses on grains, oils/oilseeds, cotton and sugar. The Company�� operations consist of over 150 mining and metallurgical sites, offshore oil production assets, farms and agricultural facilities. The Company is a producer and marketer of over 90 commodities, such as mobile phones, bicycles, cutlery, plastics and electricity. Effective January 2, 2014, Post Holdings Inc acquired Agricore United Holdings Inc from Viterra Inc, a unit of Glencore Xstrata PLC, and the transaction also included Dakota Growers Pasta Company, Inc. Advisors' Opinion:

• [By Jay Silverman]

  The CEO (Erck), CFO (Phillips), and CMO (Glenn) are a solid management team, well-experienced in their respective roles, and have a sound working chemistry and quiet confidence.

Hot Information Technology Stocks To Buy Right Now: Titan Pharmaceuticals Inc (TTNP.OB)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By C.R. Jackson]

  Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.